Related Experiment Videos
[Antithrombotic therapy in acute myocardial infarct]
1I. interná klinika LFUK v Bratislave, Bratislava, Slovakia.
Insights
Antiplatelet therapy is crucial for preventing and treating acute coronary syndromes caused by coronary artery thrombosis. Heparin and newer anticoagulants show promise, but antiplatelet agents are often preferred due to bleeding risks associated with oral anticoagulants.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Research
Context:
- Acute coronary syndromes (ACS) are primarily caused by thrombotic occlusion of coronary arteries.
- Antiplatelet therapy plays a significant role in the prevention and treatment of ACS.
- Anticoagulation, particularly with heparin, is also justified in ACS management.
Purpose:
- To review the current therapeutic strategies for managing coronary artery thrombosis and acute coronary syndromes.
- To evaluate the role of various anticoagulants, including heparin, coumarin derivatives, and newer agents, in ACS treatment.
- To discuss the comparative efficacy and risks of different antithrombotic therapies.
Summary:
- Antiplatelet therapy is a cornerstone in managing acute coronary syndromes (ACS) due to coronary artery thrombosis.
- Heparin and its derivatives are essential adjuncts, especially with thrombolytics like alteplase (t-PA).
- While oral anticoagulants like coumarin derivatives have specific indications (e.g., atrial fibrillation), antiplatelet therapy is often preferred for ACS due to bleeding risks. Emerging therapies include direct thrombin inhibitors and glycoprotein IIb/IIIa antagonists.
- Ongoing research explores low-molecular-weight heparin and comparisons between low-dose aspirin and coumarin derivatives.
Impact:
- Provides a comprehensive overview of antithrombotic strategies for ACS.
- Highlights the evolving landscape of anticoagulant and antiplatelet therapies.
- Informs clinical decision-making regarding the optimal use of anticoagulants and antiplatelet agents in patients with coronary ischaemia.
Abstract:
Thrombotic occlusion of coronary arteries is the reason of most acute coronary syndromes. A significant role in their prevention and therapy is taken by antiplatelet therapy. Acute coronary syndrome justifies also the use of anticoagulation therapy, name by heparin. The adjuvant therapy by means of heparin in thrombolysis seems to be necessary especially when alteplase (t-PA) is used. Peroral anticoagulants represent a further therapeutical procedure in patients with coronary ischaemia. Regarding the increased risk of bleeding, the cost and difficulties coinciding with therapy by cumarine derivates, the antiplatelet therapy is currently preferred. Cumarine derivates, however, should be used in patients with simultaneous atrial fibrillation, venous thromboembolism and it should be considered in patients with heart failure and pre-thrombotic states. Studies aimed at the assessment of the role of low-molecular heparin in acute coronary ischaemia currently take place. Encouraging results are gained from experience with high effective direct inhibitors of thrombin (e.g. hirudin) and antagonists of glycoprotein IIb/IIIa. It seems that they soon will find justification in the therapy of arterial thrombosis. Interesting field of the research is represented by the studies which compare low doses of acetylosalicylic acid with low doses of cumarine derivates. (Ref. 43.)